CA - Shockwave stock dips on Neovasc acquisition despite prelim Q4 revenue beat
- Shockwave Medical ( NASDAQ: SWAV ) reported preliminary Q4 revenue and outlook for FY2023 which seen above analysts estimates.
- In addition, Shockwave announced the acquisition of Neovasc ( NASDAQ: NVCN ) for an enterprise value of ~$100M plus certain contingent payments.
- The company expects preliminary Q4 revenue between $143M and $144M, up +70% to +71% Y/Y ( consensus $141.51M).
- Q4 2022 U.S. Coronary preliminary revenue expected between $81M and $82M.
- Shockwave noted that preliminary full year 2022 revenue is anticipated to be between $489M and $490M, an increase of 106% to 107% Y/Y ( consensus $487.20M).
- Full year U.S. Coronary preliminary revenue is expected in the range of $288M to $289M by the company.
- Outlook :
- Shockwave projects full year 2023 revenue to be between $660M and $680M, growth of +35% to +39% over 2022, consensus for 2023 $635.39M).
- Shockwave has an earnings conference call on Feb. 16.
- SWAV -8.87% to $184 premarket Dec. 17
For further details see:
Shockwave stock dips on Neovasc acquisition despite prelim Q4 revenue beat